MedTrace Logo

Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis

NCT01146561 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-03-23

Study results available
· View outcomes & findings →

Summary

Tanezumab is effective in reducing the pain associated with chronic pancreatitis.

Conditions

  • Chronic Pancreatitis

Interventions

BIOLOGICAL

Tanezumab

single administration of tanezumab 20 mg sub-cutaneously

OTHER

Placebo

single administration of placebo to match tanezumab, sub-cutaneously

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-13
Primary Completion
2011-03-22
Completion
2011-03-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01146561 on ClinicalTrials.gov